Frank Mottola - 22 Feb 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
22 Feb 2024
Net transactions value
-$9,360
Form type
4
Filing time
26 Feb 2024, 17:00:55 UTC
Previous filing
16 Nov 2023
Next filing
27 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Award $0 +750 +13% $0.000000 6,646 22 Feb 2024 Direct F1
transaction SUPN Common Stock Tax liability $9,360 -335 -5% $27.94 6,311 22 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -750 -33% $0.000000 1,500 22 Feb 2024 Common Stock 750 Direct F3, F4
transaction SUPN Restricted Stock Unit Award $0 +5,000 $0.000000 5,000 22 Feb 2024 Common Stock 5,000 Direct F3, F5
transaction SUPN Employee Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 22 Feb 2024 Common Stock 25,000 $27.94 Direct F6
transaction SUPN Performance Share Unit Award $0 +990 $0.000000 990 22 Feb 2024 Common Stock 990 $0.000000 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 215 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F3 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F4 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
F5 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
F6 The option vests in four equal annual installments beginning on February 22, 2025.
F7 On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.